Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody

DRUG2 trials

Sponsors

Hoffmann-La Roche

Conditions

Breast NeoplasmsTumors

Phase 1

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

CompletedNCT03280563

Hoffmann-La RocheBreast Neoplasms

Start: 2017-12-22End: 2024-09-26Updated: 2025-11-07

Phase 2

A Study of Atezolizumab in Advanced Solid Tumors

CompletedNCT02458638

Hoffmann-La RocheTumors

Start: 2015-07-16End: 2020-07-28Updated: 2021-06-04

Related Papers

Abstract PS12-08: MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients metastatic disease

Cancer Research2024-05-026 citations

Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers.

2022-03-1628 citations

Abstract PD10-04: Phase Ib/II open-label, randomized trial of atezolizumab (atezo) with ipatasertib (ipat) and fulvestrant (fulv) vs control in MORPHEUS-HR+ breast cancer (M-HR+ BC) and atezo with ipat vs control in MORPHEUS triple negative breast cancer (M-TNBC)

Cancer Research2022-02-153 citations

Abstract OT2-06-04: MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy combinations in patients with hormone receptor–positive and triple-negative breast cancer

Cancer Research2019-02-1511 citations

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Annals of Oncology2018-10-0119 citations